Opinion|Videos|February 7, 2025
Discontinuing Versus Switching BTK Inhibitors for Toxicity
Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor discontinuation after 2+ years of therapy opens up new treatment strategy considerations, with decisions between discontinuation vs switching to alternative BTK inhibitor (BTKi) therapy being influenced by factors such as depth and duration of response, toxicity severity, patient preferences regarding adverse effects and treatment schedules, and quality-of-life considerations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The ASH abstract by Mansour and colleagues suggests that for patients who have been on BTK inhibitors for more than 2 years, discontinuing therapy and observing the patient off-treatment might be an option, rather than switching to another BTKi immediately. What is your interpretation of this approach, and what factors would influence your decision to discontinue BTKi therapy due to toxicity instead of switching to an alternative BTKi?
- How should patient preferences regarding adverse effects, treatment schedules, and efficacy trade-offs influence the decision to switch or continue BTKi therapy?
- Consider reviewing the abstract by Ailawadhi and colleagues on patient preferences for BTKi.
Advertisement
Related to this article
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Advertisement
Advertisement
Trending on AJMC
1
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
2
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
3
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
4
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
5